Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Ronald L. Hanson"'
Autor:
Zhiwei Guo, Animesh Goswami, Ronald L. Hanson, Francisco González-Bobes, Michaël D. B. Fenster
Publikováno v:
Journal of Molecular Catalysis B: Enzymatic. 133:20-26
Racemic α-substituted ketones were converted to the corresponding chiral alcohols with high diastereo- and enantioselectivities using enzymatic reduction with concomitant dynamic kinetic resolution. Reductions of N-protected α-amino ketones by micr
Publikováno v:
Advanced Synthesis & Catalysis. 358:2077-2082
The concise synthesis of a pharmaceutical candidate is described. The chiral core of the molecule is assembled using an aza-benzoin condensation and a dynamic kinetic resolution (DKR) as the key reactions. This enables superb control of the regio-, d
Autor:
Animesh Goswami, Feng Qiu, Carl P. Decicco, Andrew T. Pudzianowski, Quentin Michaudel, Adrienne A. Tymiak, Patrick Y.S. Lam, Samuel J. Bonacorsi, Yingru Zhang, Benjamin P. Vokits, Bei Wang, Brad D. Maxwell, Bang-Chi Chen, Ronald L. Hanson, Jun Dai, Arvind Mathur, Dauh-Rurng Wu, Scott A. Shaw, W. Griffith Humphreys, Shun Su, Phil S. Baran, Janet Caceres Cortes, Balu Balasubramanian, Ruth R. Wexler, Zhiwei Guo, Rulin Zhao, Dawn Sun, Wenying Li, Li Peng, Kevin Cao
Publikováno v:
The Journal of Organic Chemistry. 80:7019-7032
Clopidogrel is a prodrug anticoagulant with active metabolites that irreversibly inhibit the platelet surface GPCR P2Y12 and thus inhibit platelet activation. However, gaining an understanding of patient response has been limited due to imprecise und
Autor:
Animesh Goswami, Ramesh N. Patel, Zhiwei Guo, Xiang-Yang Ye, Steven L. Goldberg, Ronald L. Hanson, Jeffrey A. Robl, Thomas P. Tully
Publikováno v:
Organic Process Research & Development. 18:960-968
An enzymatic reduction process was developed to convert the ketone 2-(6-oxo-2-phenyladamantan-2-yl)acetic acid to the chiral alcohol 2-((2S, 6S)-6-hydroxy-2-phenyladamantan-2-yl)acetic acid and to ...
Autor:
Steven J. Walker, Vidyhashankar Ramamurthy, Jun Li, Shung Wu, David K. Leahy, John D. Dimarco, Brad D. Maxwell, Daniel M. Camac, Joseph R. Taylor, Akbar Nayeem, Zhiwei Guo, James J. Li, Xiang-Yang Ye, Frederick Moulin, Paul E. Morin, Stepen P O’Connor, Haixia Wang, Jeffrey A. Robl, Rachel Zebo, Mark S. Kirby, Thomas Harrity, Joel C. Barrish, Timothy W. Harper, Lawrence L Kennedy, Rajasree Golla, Atsu Apedo, Bogdan Sleczka, Yi-Xin Li, David S. Yoon, Bin He, Steven Sheriff, Ramakrishna Seethala, Nathan Morgan, Mengmeng Wang, Randolph P. Ponticiello, Raymond P. Scaringe, Stephanie Y. Chen, Jianqing Li, Zhenqiu Hong, Ronald L. Hanson, David A. Gordon
Publikováno v:
Journal of medicinal chemistry. 60(12)
BMS-816336 (6n-2), a hydroxy-substituted adamantyl acetamide, has been identified as a novel, potent inhibitor against human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme (IC50 3.0 nM) with >10000-fold selectivity over human 11β-hydrox
Autor:
Steven Tymonko, Ronald L. Hanson, Matthew W. Haley, Annie Tam, Animesh Goswami, Zhongmin Xu, Ian S. Young
Publikováno v:
Organic Process Research & Development. 19:1360-1368
A scalable synthesis of (R,R)-2,6-dimethyldihydro-2H-pyran-4(3H)-one is reported. Key to this strategy is the Ti(OiPr)4-catalyzed Kulinkovich cyclopropanation of silyl protected (R)-ethyl 3-hydroxybutanoate, and subsequent oxidative fragmentation of
Publikováno v:
Organic Process Research & Development. 17:693-700
(R)-5,5,5-Trifluoronorvaline, an intermediate for a γ-secretase inhibitor (BMS-708163) under development, was initially prepared from the corresponding keto acid using a commercially available d-amino acid dehydrogenase for reductive amination and g
Autor:
Qi Gao, Justin B. Sausker, Reising Nathan, Ronald L. Hanson, Chung-Pin H. Chen, Jun Li, Dong Lin, Yadagiri Pendri, Daniel Hsieh, Xuebao Wang, Brenda Remy, William A. Nugent, R. Brent Nielsen, Sandra L. Quinlan, William L. Parker, Rodney L. Parsons, Reginald O. Cann
Publikováno v:
Organic Process Research & Development. 16:1953-1966
(R)-N-(3-(7-Methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)piperazine-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (1) is a potent calcitonin gene-related peptide (CGRP) receptor antagonist. We have develop
Autor:
Ling Chen, Qi Gao, Zhiwei Guo, Masano Sugiyama, Cuniere Nicolas, Lopa V. Desai, Jason Zhu, Yi Hsiao, Thorsten Rosner, Yu Fan, Collin Chan, David K. Leahy, Guanglin Luo, Ronald L. Hanson
Publikováno v:
Organic Letters. 14:4938-4941
An enantioselective synthesis of the CGRP antagonist BMS-846372, amenable to large scale preparation, is presented. This new synthesis showcases a chemo- and enantioselective reduction of a cyclohepta[b]pyridine-5,9-dione as well as a Pd-catalyzed al
Autor:
Richard Doyle, Robert M. Johnston, Wei Ding, Yeoun jin Kim, Changhong Wan, Yeung Y. Chan, Mian Gao, Olav Lyngberg, James William Bryson, Deepa Calambur, Mark R. Witmer, Stanley R. Krystek, Ronald L. Hanson, Ehrlic Lo, Steven H. Chan, Animesh Goswami, Nuria de Mas, Steven L. Goldberg, Antonio Ramirez
Publikováno v:
Bioconjugate chemistry. 27(5)
A disulfide-bridged peptide drug development candidate contained two oligopeptide chains with 11 and 12 natural amino acids joined by a disulfide bond at the N-terminal end. An efficient biotechnology based process for the production of the disulfide